UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Increases Stake in Twist Bioscience Corporation $TWST

Key Points

• UBS Asset Management increased its stake in Twist Bioscience Corporation by 186.1% in the first quarter, owning 2,442,262 shares worth approximately $95.9 million.
• Research analysts have a consensus rating of "Moderate Buy" for TWST stock, with an average target price of $49.40, showing strong investor interest.
• Twist Bioscience's stock price has fluctuated between a 12-month low of $24.07 and a high of $55.33, indicating volatility in the market.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 186.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,442,262 shares of the company's stock after purchasing an additional 1,588,587 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 4.08% of Twist Bioscience worth $95,883,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of TWST. Versant Capital Management Inc raised its holdings in Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after acquiring an additional 580 shares during the period. GAMMA Investing LLC lifted its stake in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after purchasing an additional 303 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Twist Bioscience in the 4th quarter valued at approximately $58,000. Bayforest Capital Ltd lifted its stake in Twist Bioscience by 49.3% in the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after purchasing an additional 1,604 shares during the last quarter. Finally, Pallas Capital Advisors LLC bought a new position in Twist Bioscience in the 1st quarter valued at approximately $201,000.

Twist Bioscience Stock Performance

TWST stock traded up $0.41 during mid-day trading on Monday, hitting $25.72. The company had a trading volume of 1,635,745 shares, compared to its average volume of 1,300,645. The firm has a market cap of $1.55 billion, a PE ratio of -17.74 and a beta of 2.31. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The stock's fifty day moving average price is $30.32 and its two-hundred day moving average price is $34.09.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the transaction, the chief financial officer owned 103,569 shares of the company's stock, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 2,265 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the transaction, the chief executive officer directly owned 634,740 shares of the company's stock, valued at approximately $16,350,902.40. This represents a 0.36% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,911 shares of company stock valued at $288,159. 3.01% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TWST shares. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI set a $46.00 price target on shares of Twist Bioscience in a research note on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.